Understand what your hormone testing results really mean
See your biomarkers in context with a comprehensive panel.
- CLIA-certified labs
- HIPAA compliant
- Personalized health protocol
Benign prostatic hyperplasia and the PSA story
BPH biomarkers are measurable signals in blood that come from the prostate and mirror how large and active the gland has become with benign overgrowth. The core marker is prostate‑specific antigen (PSA), a protein made by prostate lining cells that normally stays inside prostate ducts and semen; when the gland enlarges or its lining turns over faster, more leaks into the bloodstream. Tests that look at PSA and its related forms—free PSA (unbound PSA), precursor PSA (proPSA, especially [-2]proPSA), and human kallikrein 2 (hK2)—capture different facets of prostate biology (kallikrein‑related peptidases). Together they reflect gland volume, ductal integrity, and secretory activity, giving a biochemical readout of BPH rather than just symptom scores. No single blood marker “proves” BPH, but patterns in these prostate‑derived proteins help separate benign enlargement from other prostate conditions, indicate when more evaluation may be useful, and provide a simple way to track the gland’s behavior over time. Hormone signals that drive growth (androgens such as testosterone and dihydrotestosterone) are related context but are not prostate‑specific biomarkers.
Why a PSA pattern matters in prostate enlargement
Blood testing for BPH focuses on prostate-derived markers—especially total PSA and the fraction that circulates unbound (Free PSA or percent‑free). Because PSA production rises with gland size and epithelial turnover, these markers translate prostate biology into a signal about urinary tract function, bladder workload, and even kidney stress when outflow is obstructed. Total PSA tends to increase with age and prostate volume; age-adjusted reference ranges are used, but for most men the healthiest pattern is a lower total PSA for age. Percent‑free PSA helps interpret why PSA is elevated: higher percentages are more consistent with benign overgrowth, while lower percentages can indicate a greater likelihood of cancer. In BPH, total PSA that sits toward the mid-to-higher end of the age range often reflects a larger prostate and higher risk of weak stream, urgency, or nocturia; a higher percent‑free PSA in that setting supports a benign process. When values are low—low total PSA, often with a higher percent‑free—this usually means a smaller gland, less epithelial activity and inflammation, and minimal obstruction. Younger men typically show very low levels; in older men, low PSA suggests low BPH burden. Urinary symptoms, if present despite low values, may be driven more by bladder function than by prostate blockage. Certain medicines that shrink the prostate can lower PSA and require context for interpretation. Big picture: PSA biology sits at the crossroads of hormones, growth signaling, and inflammation. Tracking total and free PSA connects prostate size to bladder health and kidney protection, and, alongside exam and imaging, helps distinguish benign enlargement from malignancy—clarifying long‑term risks from urinary retention to renal impairment.
Test 100+ biomarkers from home
One blood draw. A full picture of your health, explained in plain language.
Test 100+ biomarkers from home
One blood draw. A full picture of your health, explained in plain language.
What PSA can and can't say about BPH
Benign prostatic hyperplasia (BPH) is a common, non-cancerous enlargement of the prostate gland that can affect urinary, reproductive, and overall metabolic health, especially as men age. At Superpower, we assess BPH risk and status by measuring two key blood biomarkers: PSA total and free PSA. These markers help us understand how the prostate is functioning and whether its growth is stable or showing signs of abnormality, which can impact energy, urinary flow, and even aspects of cardiovascular and immune system health. PSA total (prostate-specific antigen) is a protein produced by both normal and enlarged prostate tissue. Free PSA refers to the fraction of PSA circulating in the blood that is not bound to other proteins. In BPH, both PSA total and free PSA can be elevated, but the ratio between them helps distinguish benign enlargement from more concerning conditions like prostate cancer. A higher proportion of free PSA relative to total PSA is more typical of BPH, while a lower ratio may warrant further investigation. Stable and healthy prostate function is reflected by PSA levels that remain within an expected range for age and by a Free-to-Total PSA ratio that supports a benign process. These markers, when interpreted together, provide insight into the balance and integrity of prostate tissue, helping to monitor for changes that could affect urinary and systemic health. It’s important to note that PSA levels can be influenced by age, recent ejaculation, prostate manipulation, infections, and certain medications. Laboratory methods and reference ranges may also vary, so results are best interpreted in context with clinical history and other findings.
Frequently Asked Questions
References
- Polascik TJ, Oesterling JE, Partin AW (1999). Prostate specific antigen: a decade of discovery--what we have learned and where we are going. *The Journal of Urology*, *162*(2), 293-306. https://doi.org/10.1016/s0022-5347(05)68543-6
- Catalona WJ, Smith DS, Wolfert RL, Wang TJ, Rittenhouse HG, Ratliff TL, Nadler RB (1995). Evaluation of percentage of free serum prostate-specific antigen to improve specificity of prostate cancer screening. *JAMA*, *274*(15), 1214-1220. https://doi.org/10.1001/jama.1995.03530150038031
- Jung K, Brux B, Lein M, Knabich A, Sinha P, Rudolph B, Schnorr D, Loening SA (1999). Determination of alpha1-antichymotrypsin-PSA complex in serum does not improve the differentiation between benign prostatic hyperplasia and prostate cancer compared with total PSA and percent free PSA. *Urology*, *53*(6), 1160-1168. https://doi.org/10.1016/s0090-4295(99)00080-1
- Jansen FH, van Schaik RH, Kurstjens J, Horninger W, Klocker H, Bektic J, Wildhagen MF, Roobol MJ, Bangma CH, Bartsch G (2010). Prostate-specific antigen (PSA) isoform p2PSA in combination with total PSA and free PSA improves diagnostic accuracy in prostate cancer detection. *European Urology*, *57*(6), 921-927. https://doi.org/10.1016/j.eururo.2010.02.003
- Sokoll LJ, Sanda MG, Feng Z, Kagan J, Mizrahi IA, Broyles DL, Partin AW, Srivastava S, Thompson IM, Wei JT, Zhang Z, Chan DW (2010). A prospective, multicenter, National Cancer Institute Early Detection Research Network study of [-2]proPSA: improving prostate cancer detection and correlating with cancer aggressiveness. *Cancer Epidemiology, Biomarkers & Prevention*, *19*(5), 1193-1200. https://doi.org/10.1158/1055-9965.epi-10-0007
- Verhamme KM, Dieleman JP, Bleumink GS, van der Lei J, Sturkenboom MC, Triumph Pan European Expert Panel. (2002). Incidence and prevalence of lower urinary tract symptoms suggestive of benign prostatic hyperplasia in primary care--the Triumph project. *European Urology*, *42*(4), 323-328. https://doi.org/10.1016/s0302-2838(02)00354-8
